These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Mohr JF; Murray BE Clin Infect Dis; 2007 Jun; 44(12):1536-42. PubMed ID: 17516395 [TBL] [Abstract][Full Text] [Related]
3. Is vancomycin obsolete? Legendre D Am J Health Syst Pharm; 2009 Jun; 66(11):977-8. PubMed ID: 19451604 [No Abstract] [Full Text] [Related]
4. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Kitzis MD; Goldstein FW Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555 [TBL] [Abstract][Full Text] [Related]
5. Vancomycin: does it still have a role as an antistaphylococcal agent? Deresinski S Expert Rev Anti Infect Ther; 2007 Jun; 5(3):393-401. PubMed ID: 17547504 [TBL] [Abstract][Full Text] [Related]
6. Treatment of severe infections caused by Staphylococcus aureus: a change in the vancomycin paradigm? Aranha Camargo LF Shock; 2008 Oct; 30 Suppl 1():67-9. PubMed ID: 18704006 [TBL] [Abstract][Full Text] [Related]
8. Multidrug and vancomycin resistance among clinical isolates of Olufunmiso O; Tolulope I; Roger C Afr Health Sci; 2017 Sep; 17(3):797-807. PubMed ID: 29085408 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus. Nagura J; Kijima K; Kurazono M; Takahata S; Sugano T; Tanaka Y; Hirai Y; Yamada K; Takayama Y; Shitara E; Yonezawa M Antimicrob Agents Chemother; 2005 Aug; 49(8):3526-8. PubMed ID: 16048975 [TBL] [Abstract][Full Text] [Related]
10. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849 [TBL] [Abstract][Full Text] [Related]
13. Key considerations in the treatment of complicated staphylococcal infections. Jones RN Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Madrigal AG; Basuino L; Chambers HF Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918 [TBL] [Abstract][Full Text] [Related]
15. D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus. Tabuchi F; Matsumoto Y; Ishii M; Tatsuno K; Okazaki M; Sato T; Moriya K; Sekimizu K J Antibiot (Tokyo); 2017 Jul; 70(8):907-910. PubMed ID: 28588223 [TBL] [Abstract][Full Text] [Related]